In conclusion, we have demonstrated that the phenotypic switch induced by TGFβ in NSCLC, which leads to the acquisition of a more invasive and aggressive phenotype and is associated with αvβ6 overexpression, is reversed by the treatment with dual conjugated drugs of type 1 and 2 that target RTK pathways in αvβ6 integrin-expressing cells. The gene discussed is TGFB1; the disease is non-small cell lung carcinoma.